Blis Technologies Limited · NZX:BLT
Blis Technologies — Shareholder Meeting (July 2022)
30 slides from Blis Technologies's shareholder meeting presentation, Jul 21, 2022
Slide 1: 2022 Annual Shareholder Meeting
2022 ANNUAL SHAREHOLDER MEETING 21 July 2022
Slide 2: Attendees Question and Voting Process
Attendees Question and Voting Process. Voting and asking questions Voting Card Question box 1
Slide 3: Meeting Agenda
Meeting Agenda. Business of the Meeting Chairperson’s Address • Geoff Plunket Chief Executive Officer’s Address • Brian Watson Ordinary Resolutions • Re-election of Dr Alison Stewart as a director • Election of Mr Tom Rönnlund as a director • Election of Ms Amelia (Aimee) McCammon as a director • Di
Slide 4: Board of Directors
Board of Directors. Geoffrey (Geoff) Plunket Antony (Tony) Balfour Amelia (Aimee) Chair, Independent non-executive director Deputy Chair, Independent McCammon non-executive director Independent non-executive director Member of Audit and Risk Committee and Remuneration Committee Member of Remuneratio
Slide 5: Disclaimer
Disclaimer. In making an investment decision, investors must rely involve significant elements of subjective judgement Information on their own examination of the Company, including the and assumptions as to future events which may or may The information in this presentation is an overview and merit
Slide 6: Summary FY22
Summary FY22. Revenue (NZ$m) EBITDA (NZ$m) 2.1m $ $12.0 $2.0 10.6m $ 10.6m $ 1.0m $ 0.9m $ 9.0m $ $9.0 8.2m $ $ $6.0 0.4m -$ 5.3m $ -$2.0 $3.0 2.1m -$ $ -$4.0 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22
Slide 7: Post-FY22 strategic review of operations
Post-FY22 strategic review of operations. Focus on what we do best and how we continue to deliver to our purpose – Developing breakthrough probiotic solutions for the health and wellbeing of global consumers Focus operations with immediate effect: » B2B opportunities and licensing of our technology
Slide 8: CEO Address
CEO Address. Brian Watson Chief Executive Officer (CEO)
Slide 9: The BLIS Leadership Team
The BLIS Leadership Team. Brian Watson Richard Wingham Chief Executive Officer (CEO) Chief Financial Officer (CFO) Dr John Hale Frank Spiewack Jennifer Walker Chief Technology Officer (CTO) Commercial Director eCommerce and Marketing Director
Slide 10: Probiotic supplements market overview
Probiotic supplements market overview. Forecast CAGR Global Probiotic (2021 – 2026) Supplements Market 2021 * ROW North America -1% North Europe 4.8% America Asia Pacific 10% Europe 3% 25.2% 34.4% Total Global Market 3.7% Asia Pacific 35.6% * Euromonitor International report for the International Pr
Slide 11: Summary FY22
Summary FY22. Revenue (NZ$m) EBITDA (NZ$m) 2.1m $ $12.0 $2.0 10.6m $ 10.6m $ 1.0m $ 0.9m $ 9.0m $ $9.0 8.2m $ $ $6.0 0.4m -$ 5.3m $ -$2.0 $3.0 2.1m -$ $ -$4.0 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22
Slide 12: Summary FY22 continued
Summary FY22 continued. Revenue breakdown (NZ$m) Revenue by region (NZ$m) $12.0 $6.0 $10.0 $5.0 $8.0 $4.0 $6.0 $3.0 $4.0 $2.0 $2.0 $1.0 $ $ FY18 FY19 FY20 FY21 FY22 Asia Pacific Europe North America Ingredient Finished Product Licencing FY21 FY22
Slide 13: FY22 summary
FY22 summary. Probi strategic partnership New market activity Ingredient supply Patent Filings » Royalty stream based on » Canada Retail – » Commercial supply of » Provisional BLIS K12™ licensing of Blis probiotic Pharmacies and natural Dairy Free BLIS K12™ filing new use against strains health stor
Slide 14: Probi Strategic Partnership – delivering significant value
Probi Strategic Partnership – delivering significant value. Primary opportunities: Broader opportunities: • R&D – shared expertise to develop innovative probiotic solutions • Scientific and clinical validation of probiotic health benefits Blis Probi • Contract manufacture – both fermentation » Subst
Slide 15: A word from Probi CEO and Blis board member
CONFIDENTIAL CONFIDENTIAL bi Probi Probi. A word from Probi CEO and Blis July, 2021 Board member Tom Rönnlund
Slide 16: Post-FY22 strategic review of operations
Post-FY22 strategic review of operations. Focus on what we do best and how we continue to deliver to our purpose – Developing breakthrough probiotic solutions for the health and wellbeing of global consumers Focus operations with immediate effect: » B2B opportunities and licensing of our technology
Slide 17: Focus on our core strength
Focus on our core strength. We have a track record of We have developed deep This capability underpins delivering breakthrough knowledge and capability attractive assets for B2B probiotic solutions through related to novel product revenue opportunities our own R & D formats Health targets include »
Slide 18: Business model changes
Business model changes. Current model Refreshed model Emphasis on growth through D2C ecommerce and retail channels in Emphasis on B2B revenue opportunities leveraging NZ, USA, Canada partners’ market strengths to drive scale 3 health and wellbeing targets 3 health and wellbeing targets » ENT/ immuni
Slide 19: In summary
In summary. Core business will narrow Significant level of current Stop investing ourselves in and refocus to those parts operating activities will opening new B2C market of the value chain where continue: opportunities Blis: » Probi partnership » Has the expertise to deliver value; » B2B: Internati
Slide 20: Q1 update
Q1 update. Unaudited results for the quarter ending 30 June 2022 (Q1 FY23) Revenue and EBITDA are in-line with our expectations $ 2.3m Total revenue for the quarter $ 0.3m EBITDA loss Outlook. » The global probiotic market is forecast to grow at an average 3.7% per annum to 2026 , including Asia and
Slide 21: Summary
Summary. THE PROBI - OUR BUSINESS LONG TERM FOCUS - STRENGTH MODEL - B2B STRATEGIC TRANSITION - PROBIOTIC SELLING AND PARTNERSHIP UNPROFITABLE INNOVATION PARTNERSHIPS FOR GROWTH CHANNELS
Slide 22: Questions
Questions. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 23: Attendees Question Process
Attendees Question Process. Voting and asking questions Voting Card Question box 1
Slide 24: Resolutions
Resolutions. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 25: Attendees Voting Process
Attendees Voting Process. Voting and asking questions Voting Card Question box 1
Slide 26: Resolution 1
Resolution 1. That Dr Alison Stewart be re-elected as a director of the Company. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 27: Resolution 2
Resolution 2. That Mr Tom Rönnlund be elected as a director of the Company. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 28: Resolution 3
Resolution 3. That Ms Amelia (Aimee) McCammon be elected as a director of the Company. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 29: Resolution 4
Resolution 4. That the Directors be authorised to fix the remuneration of the auditors for the ensuing year. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 30: General Business
General Business. i. B LIS Technologies